

Table 3 (web only): Trial characteristics

Trial	Aim	Phase	Funding	Multicentre	Country	Sufficiently powered	Follow up (months)
Kelly 2001[24]	To determine whether PAX+CARB offered a survival advantage over VNB+CIS	III	Public Health Service Cooperative Agreement grants (National Cancer Institute), Glaxo Wellcome, Inc., Bristol-Meyers Squibb	Yes	USA	Yes	24
Scagliotti 2002[9]	To evaluate whether GEM+CIS or PAX+CARB offer any advantage over VNB+CIS	III	Eli Lilly	Yes	Italy	Yes	24
Schiller 2002[34]	To determine whether CIS+GEM, CIS+DOC or CARB+PAX are superior to CIS+PAX	Unclear	National Institutes of Health	Yes	USA	Yes	24
Fossella 2003[10]	To investigate whether DOC+PLAT regimens improve survival and affect QoL compared with VNB+CIS	III	Aventis Pharma	Yes	Australia, Canada, Europe, Israel, Latin America, Lebanon, New Zealand, South Africa, USA	Yes	24
Gebbia 2003[25]	To compare VNB+CIS with GEM+CIS, and to sequential CTX with GEM+IFOS followed by VNB+CIS or VNB+CIS followed by GEM+IFOS	III	NR	Yes	Italy	No	12

Trial	Aim	Phase	Funding	Multicentre	Country	Sufficiently powered	Follow up (months)
Gridelli 2003[8]	To assess whether GEM+VNB had QoL benefits without influencing negatively on survival, compared with GEM+CIS and VNB+CIS	III	Clinical Trials Promoting Group Italy, Eli Lilly Canada, Associazione Italiana per la Ricerca sul Cancro	Yes	Canada, Italy	Yes	12
Smit 2003[11]	To compare efficacy of PAX+CIS vs GEM+CIS and PAX+GEM	III	National Cancer Institute	Yes	Belgium, Egypt, Germany, Netherlands, Spain	Yes	12
Chen 2004[19]	To evaluate the efficacy of weekly PAX+CIS vs VNB+CIS	II	NR	No	Taiwan	Yes	12
Douillard 2005[20]	To evaluate DOC+CIS vs VNB+CIS and the effect of cross-over to single-agent DOC or VNB at disease progression	II	Laboratoire Aventis France	Yes	France	Yes	36
Martoni 2005[26]	To determine whether GEM+CIS offers any advantages over VNB+CIS	III	NR	Yes	Italy	Yes	24
Thomas 2006[21]	To evaluate the efficacy and safety of GEM+CARB	II	Lilly France, l'assistance publique/H ^o pitaux de Marseille	Yes	France	Unclear	11
Chen 2007[22]	To evaluate the efficacy of DOC+CIS vs VNB+CIS	II	NR	No	Taiwan	Yes	12

Trial	Aim	Phase	Funding	Multicentre	Country	Sufficiently powered	Follow up (months)
Helbekkmo 2007[27]	To compare VNB+CARB and GEM+CARB for efficacy, HRQOL and toxicity	III	NR	Yes	Norway	Yes	12
Langer 2007[23]	To evaluate PAX+CARB vs GEM+CIS	II	Public Health Service Grants, National Cancer Institute, National Institutes of Health and the Department of Health and Human Services	Yes	USA	No	24
Ohe 2007[28]	To compare efficacy and toxicity of PAX+CARB, GEM+CIS, VNB+CIS vs IRIN+CIS	III	Bristol-Myers Japan, Eli Lilly Japan, Kyowa Hakko Kogyo Co. Ltd, Japan.	Yes	Japan	Yes	24
Chang 2008[35]	To evaluate the safety and efficacy of GEM+CIS vs VNB+CIS	Unclear	NR	No	Taiwan	Unclear	12
Scagliotti 2008[4]	To compare the OS of PEM+CIS vs GEM+CIS	III	Eli Lilly	Yes	Belgium, Brazil, Canada, Denmark, Germany, India, Italy, Korea, Netherlands Poland, Turkey, USA,	Yes	24
Gronberg 2009[29]	To compare PEM+CARB vs GEM+CARB	III	Eli Lilly	Yes	Norway	Yes	12

Trial	Aim	Phase	Funding	Multicentre	Country	Sufficiently powered	Follow up (months)
Mok 2009[5]and Fukuoka 2011[36]	To compare efficacy, safety, and adverse event profile of GEF vs PAX+CARB	III	AstraZeneca	Yes	Hong Kong, elsewhere in China, Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, and Thailand	Yes	17
Tan 2009[30]	To compare efficacy of day 1 intravenous VNB and day 8 oral VNB+CIS vs DOC+CIS	III	Institut de Recherche Pierre Fabre	Yes	Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Israel, Italy, Mexico, Poland, Portugal, South Africa, Spain, Switzerland, Taiwan	No	12
Maemondo 2010[31]	To compare GEF vs PAX+CARB	III	Japan Society for Promotion of Science, Japanese Foundation for the Multidisciplinary Treatment of Cancer, Tokyo Cooperative Oncology Group	Yes	Japan	No	24

Trial	Aim	Phase	Funding	Multicentre	Country	Sufficiently powered	Follow up (months)
Mitsudomi 2010[32]	To compare GEF vs DOC+CIS	III	West Japan Oncology Group	Yes	Japan	Yes	40
Treat 2010[33]	To compare GEM+CARB or GEM+PAX vs PAX+CARB	III	Eli Lilly	Yes	USA	Yes	36

CARB=carboplatin; CIS=cisplatin; DOC=docetaxel; GEF=gefitinib; GEM=gemcitabine; PAX=paclitaxel; PEM=pemetrexed; VNB=vinorelbine
NR=not reported